Publikationen der Klinik für Strahlentherapie und Onkologie

Hier finden Sie die Publikationen der Klinik für Strahlentherapie und Onkologie der letzten Jahre.

Publikationen 2019

Diefenhardt M, Hofheinz RD, Martin D, Beissbarth T, Arnold D, Hartmann A, von der Grün J, Grützmann R, Liersch T, Ströbel P, Grabenbauer GG,  Rieger M, Fietkau R, Graeven U, Weitz J, Folprecht G, Ghadimi M, Rödel F, Rödel C, Fokas E. Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. Int J Cancer 2019;145:2282-2291. (Pubmed-Link).

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of sex with toxic effects, treatment adherence, and oncologic outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 randomized clinical trials of rectal cancer. JAMA Oncol 2019; epub ahead of print. (Pubmed-Link).

Chae W, Schulz M, Niesel K, Klemm F, Joyce J, Prümmer M, Brill B, Bergs J, Rödel F, Pilatus U, Sevenich L. Evaluating therapeutic response of whole brain radiotherapy in a mouse model for breast-to-brain metastasis using magnetic resonance imaging and spectroscopy. Front Oncol 2019 accepted (Pubmed-Link).

Chatzikonstantinou G, Ulrich P, Archavlis E, Zamboglou N, Strouthos I, Zoga E, Baltas D, Tselis N. Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme. J Contemp Brachytherapy 2019;11:215-220 (Pubmed-Link).

Chatzikonstantinou G, Zamboglou N, Baltas D, Ferentinos K, Bon D, Tselis N. Image-guided interstitial high-dose-rate brachytherapy for dose escalation in the radiotherapy treatment of locally advanced lung cancer: A single-institute experience. Brachytherapy 2019; epub ehead of print (Pubmed-Link).

Eder T, Hess AK, Konschak R, Stromberger C, Jöhrens K, Fleischer V, Hummel M, Balermpas P, von der Grün J, Linge A, Lohaus F, Krause M, Baumann M, Stuschke M, Zips D, Grosu A, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs S, Budach V, Tinhofer I. Interference of tumor mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: A multicenter retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Eur J Cancer. 2019;116:67-76. (Pubmed-Link).

Feczkó T, Piiper A, Pleli T, Schmithals C, Denk D, Hehlgans S, Rödel F, Vogl TJ, Wacker MG. Theranostic sorafenib-loaded polymeric nanocarriers manufactured by enhanced gadolinium conjugation techniques.  Pharmaceutics 2019,11:489. (Pubmed-Link).

Fleischmann M, Martin D, Peña-Llopis S, Oppermann J, von der Grün J, Diefenhardt M, Chatzikonstantinou G, Fokas E, Rödel C, Strebhardt K, Becker S, Rödel F, Tselis N. Association of Polo-like kinase 3 and phosphoT273 Caspase 8 with improved survival in patients with cervical squamous cell carcinoma treated with radical chemoradiotherapy and brachytherapy. Front Oncol 2019,9:742. (Pubmed-Link).

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W,  Jacobasch L, Weitz J, Folprecht G, Schlenka-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C, German Rectal Cancer Study Group. Randomized Phase II Trial on Chemoradiotherapy plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol 2019; epub ahead of print (Pubmed-Link)

Gani C, Gani N, Zschaeck S, Eberle F, Schaeffeler N, Hehr T, Berger B, Fischer SG, Claßen J, Zipfel S, Rödel C, Teufel M, Zips D. Organ Preservation in Rectal Cancer: The Patients' Perspective .Front Oncol 2019;10;9:318. (Pubmed-Link).

Hausmann J, Kubesch A, von der Grün JM, Goettlich CM, Filmann N, Tal AO, Vermehren J, Friedrich-Rust M, Wächtershäuser A, Bojunga J, Blumenstein I. Prophylactic percutaneous endoscopic gastrostomy in patients with head and neck cancer: influence on nutritional status, utilization rate and complications. Int J Clin Pract 2019; epub ahead of print. (Pubmed-Link)

Hess AK, Jöhrens K, Zakarneh A, Balermpas P, von der Grün J, Rödel C, Weichert W, Hummel M, Keilholz U, Budach V, Tinhofer I.  Characterization of the Tumor Immune Micromilieu and its Interference with Outcome After Concurrent Chemoradiation in Patients with Oropharyngeal Carcinomas. Oncoimmunology 2019;8:1614858. (Pubmed-Link).

Hess J, Unger K, Maihoefer C, Schüttrumpf L, Wintergerst L, Heider T, Weber P, Marschner S, Braselmann H, Samaga D, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Linge A, Rödel C, Stuschke M, Zips D, Zitzelsberger HF, Ganswindt U, Henke M, Belka C. A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV-infection. Clin Cancer Res 2019;25:1505-1516. (Pubmed-Link)

Hoey C, Ahmed M, Fotouhi Ghiam A, Vesprini D, Huang X, Commisso K, Commisso A, Ray J, Fokas E, Loblaw DA, He HH, Liu SK. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy. J Transl Med 2019;17:173. (Pubmed-Link).

Hörner-Rieber JH, Bernhardt D, Blanck O, Duma M, Eich H, Gerum S, Gikka E, Hass P, Henkenberens C, Herold HU, Hildebrandt G, Imhoff D, Kahl H, Janssen S, Jurianz K, Krempien R, Lautenschläger SF, Lohaus F, Mueller AC, Petersen C, Sackerer I, Scafa D, Schrade E,  Uhlmann L, Wittig A, Guckenberger M. Long-term follow-up and patterns of recurrence of oligometastatic NSCLC patients treated with pulmonary SBRT. Clin Lung Cancer 2019 in epub eahead of print (Pubmed-Link).

Klement RJ, Abbasi-Senger N, Adebahr S, Alheid H ,Allgaeuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Eble MJ, Ernst I, Gerum S, Habermehl D, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lewitzki V, Lohaus F, Ostheimer C, Papachristofilou A, Petersen C, Rieber J, Schneider T, Schrade E, Semrau R, Wachter S, Wittig A, Guckenberger M, Andratschk A. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer 2019;19:173. (Pubmed-Link)

Lang BM, Balermpas P, Bauer A, Blum A, Brölsch GF, Dirschka T, Follmann M, Frank J, Frerich B, Fritz K, Hauschild A, Heindl LM, Howaldt HP, Ihrler S, Kakkassery V, Klumpp B, Krause-Bergmann A, Löser C, Meissner M, Sachse MM, Schlaak M, Schön MP, Tischendorf L, Tronnier M, Vordermark D, Welzel J, Weichenthal M, Wiegand S, Kaufmann R, Grabbe S. S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 1: Epidemiology, Genetics and Diagnosis . J Dtsch Dermatol Ges 2019;17:94-103. (Pubmed-Link)

Linder B, Wehle A, Bonn F, Hehlgans S, Dikic I, Rödel F. Seifert V, Kögel D. Arsenic Trioxid and (-)-Gossypol synergistically target glioma stem-like cells via Inhibition of Hedgehog and Notch signaling. Cancers 2019:11:350. (Pubmed-Link)

Ludmir EB, Fuller CD, Moningi S, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Verma V, Smith BD, Smith GL, VanderWalde NA, Holliday EB, Guadagnolo BA, Stinchcombe TE, Jagsi R, Gomez DR, Minsky BD, Rödel C, Fokas E. Sex-Based Disparities Among Cancer Clinical Trial Participants. J Natl Cancer Inst 2019, epub ahead of print. (Pubmed-Link)

Martin D, Rödel F, Balermpas P, Winkelmann R, Fokas E, Rödel C. C-reactive protein-to-albumin ratio as prognostic marker for anal squamous cell carcinoma treated with chemoradiotherapy. Front Oncol 2019 accepeted (Pubmed-Link).

Martin D, Rödel C, Fokas E. Chemoradiotherapy for anal cancer: are we as good as we think? Strahlenther Onkol 2019;195:369-373. (Pubmed-Link)

Merten R, Ott O, Haderlein M, Bertz S, Hartmann A, Wullich B, Keck B, Kühn R, Rödel CM, Weiss C, Gall C, Uter W, Fietkau R. Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). Oncologist 2019; epub ahead of print. (Pubmed-Link)

Müller-Längle A, Lutz H, Hehlgans S, Rödel F, Rau K, Laube B. NMDA Receptor-mediated signaling pathways enhance radiation resistance, survival and migration in glioblastoma cells - a potential target for adjuvant radiotherapy. Cancers 2019;11:E50. (Pubmed-Link)

Montero A, Sabater S, Rödel F, Gaipl US, Ott OJ, Seegenschmiedt MH, Arenas M. Is it time to redefine the role of low-dose radiotherapy for benign disease? Ann Rheum Dis 2018 Comment, epub ahead of print. (Pubmed-Link)

Ott OJ, Micke O, Mücke R, Niewald M, Rödel F, Schäfer U, Seegenschmiedt MH, Arenas M, Frey B, Gaipl US. Low-dose radiotherapy: Mayday, mayday, we've been hit! Strahlenther Onkol 2019;195:285-288. (Pubmed-Link).

Raab M, Sanhaji M, Zhou S, Rödel F, El-Balat A, Becker S, Strebhardt K. Blocking mitotic exit of ovarian cancer cells by pharmaceutical inhibition of the Anaphase-Promoting Complex reduces chromosomal instability. Neoplasia 2019;21:363-375. (Pubmed-Link).

Rödel C, Fokas E, Gani C. Complete response after chemoradiotherapy for rectal cancer: what is the reasonable approach? Innov Surg Sci 2017;3:47-53. (Pubmed-Link).

Rödel F, Martin D, Balermpas P, Wieland U, Winkelmann R, Riekmann T, Falk S, Rödel C, Fokas E. Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. Biochim Biophys Acta Rev Cancer  2019;1871:126-137. (Pubmed-Link).

Strouthos I, Tselis N, Ferentinos K, Karagiannis E, Milickovic N, Chatzikonstantinou G, Feder O, Zamboglou N. Intraluminal high-dose-rate brachytherapy - an alternative organ-preserving approach for primary male urothelial carcinoma with panurethral involvement. Pract Radiat Oncol 2019; epub ahead of print. (Pubmed-Link).

Stera S, Balermpas P, Blanck O, Wolff R, Wurster S, Baumann R, Szücs M, Loutfi-Krauss B, Wilhelm MS, Seifert V, Rades D, Rödel C, Dunst J, Hildebrandtg,  Arnold, A, Meissner M, Kähler, KC. Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma. Melanoma Research2019;29:187-195. (Pubmed-Link)

Valentini V, Marijnen C, Beets G, Bujko K, De Bari B, Cervantes A, Chiloiro G, Coco C, Gambacorta MA, Glynne-Jones R, Haustermans K, Meldolesi E, Peters F, Rödel C, Rutten H, van de Velde C, Aristei C. The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. Radiother Oncol 2019; epub ahead of print. (Pubmed-Link).

Von der Grün J, Köhn J, Loutfi-Krauss B, Blanck O, Rödel C, Balermpas P. Second infield re-irradiation with a resulting cumulative equivalent dose (EQD2max ) of >180 Gy for patients with recurrent head and neck cancer. Head Neck 2019;41:E48-E54. (Pubmed-Link)

Von der Grün J, Winkelmann R, Meissner  M, Wieland U, Silling S, Martin D, Fokas E, Rödel C, Rödel F, Balermpas P. Merkel cell polyoma viral load and CD8+ lymphocyte infiltration predict overall survival in patients with Merkel cell carcinoma. Front Oncol 2019;9:20. (Pubmed-Link)

Von der Grün J, Rödel F, Fokas E, Guckenberger M, Rödel C, Brandts C, Balermpas P. Targeted therapies and immune-checkpoint inhibition in head and neck squamous cell carcinoma: Where do we stand and where to go. Cancers 2019;11:472. (Pubmed-Link)

Voss M, Batarfi A, Steidl E, Wagner M, Forster MT, Steinbach JP, Rödel CM, Bojunga J, Ronellenfitsch MW. Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab. J Clin Med 2019;8:pii E1608. (Pubmed-LInk)

Voss M, Franz K, Steinbach JP, Fokas E, Forster MT, Filipski K, Hattingen E, Wagner M, Breuer S. Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients. J Neurooncol 2019;142:161-169. (Pubmed-Link)

Wunderlich R, Rühle P, Deloch L, Rödel F, Fietkau R, Gaipl U, Frey B. Ionizing radiation reduces the capacity of activated macrophages to induce T-cell proliferation, but does not trigger dendritic cell-mediated non targeted effects. Int J Radiation Biol 2019;95:33-43. (Pubmed-Link)


Balermpas P, Stera S, Müller von der Grün J, Loutfi-Krauss B, Forster MT, Wagner M, Keller C, Rödel C, Seifert V, Blanck O, Wolff R. Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohort. PLoS One 2018;13:e0198692 (Pubmed-Link).

Baumann R, Chan MKH, Pyschny F, Stera S, Malzkuhn B, Wurster S, Huttenlocher S, Szücs M, Imhoff D, Keller C, Balermpas P, Rades D, Rödel C, Dunst J, Hildebrandt G and Blanck O. Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors. Front. Oncol 2018;8:171. (Pubmed-Link).

Chatzikonstantinou G, Zamboglou N, Archavlis E, Strouthos I, Zoga E, Milickovic N, Hilaris B, Baltas D, Rödel C, Tselis N. CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience. Strahlenther Onkol 2018 ;194:1171-1179 (Pubmed-Link).

Combs SE, Niyazi M, Adeberg S, Bougatf N, Kaul D, Fleischmann DF, Gruen A, Fokas E, Rödel CM, Eckert F, Paulsen F, Oehlke O, Grosu AL, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J, Kessel KA. Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). Cancer Med 2018;7:1742-1749 (Pubmed-Link).

De-Colle C, Menegakis A, Mönnich D, Welz S, Boeke S, Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, Abu Jawad J, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Belka C, Ganswindt U, Pigorsch S, Combs SE, Lohaus F, Linge A, Krause M, Baumann M, Zips D; DKTK-ROG. SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiother Oncol 2018;194:143-155. (Pubmed-Link)

Fokas E, Fietkau R, Hartmann A, Hohenberger W, Grützmann R, Ghadimi M, Liersch T, Ströbel P, Grabenbauer GG, Graeven U, Hofheinz RD, Köhne CH, Wittekind C, Sauer R, Kaufmann M, Hothorn T, Rödel C. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase 3 trial. Ann Oncol 2018;29:1521-1527 (Pubmed-Link).

Förster S, Hehlgans S, Rödel F, Otto B, Cordes N. Radiochemosensitivity and invasion of human colorectal cancer cells is regulated in an α-catenin-independent manner. Int J Oncol 2018; 52:1117- 28 (Pubmed-Link).

Gani C, Bonomo P, Zwirner K, Schroeder C, Menegakis A, Rödel C, Zips D. Organ preservation in rectal cancer - Challenges and future strategies. Clin Transl Radiat Oncol 2017;3:9-15. (Pubmed-Link)

Gani C, Grosse U, Clasen S, Kirschniak A, Goetz M, Rödel C, Zips D. Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer. Strahlenther Onkol  2018; 194:985-990. (Pubmed-Link)

Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29 (Supplement_4):iv263 (Pubmed-Link)

Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, Schadendorf D, Grabbe S, Schuler G, Fietkau R, Distel LV, Heinzerling L. Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. Br J Cancer 2018;118(6):785-792. (Pubmed-Link).

Hehlgans S, Booms P, Güllülü Ö, Sader R, Rödel C, Balermpas P, Rödel F ,Ghanaati S. Radiation sensitization of basal cell and head and neck squamous cell carcinoma by the Hedgehog pathway inhibitor vismodegib. Int J Mol Sci 2018;19:e2485 (Pubmed-Link).

Hofheinz RD, Arnold D, Fokas E, Kaufmann M, Hothorn T, Folprecht G, Fietkau R, Hohenberger W, Ghadimi M, Liersch T, Grabenbauer GG, Sauer R, Rödel C, Graeven U; German Rectal Cancer Study Group. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: A post hoc analysis of the CAO/ARO/AIO-04 phase 3 Trial. Ann Oncol 2018;29:1793-1799 (Pubmed-Link).

Karagiannis E, Leczynski A, Tselis N, Psanis E, Steckenreiter O, Milickovic N, Bon D, Strouthos I, Ferentinos K, Hass P, Gademann G, Baltas D, Zamboglou N. Inverse planning and inverse implanting for breast interstitial brachytherapy. Introducing a new anatomy specific breast interstitial template (ASBIT). Radiother Oncol 2018;128:421-427 (Pubmed-Link).

Kitz J*, Fokas E*, Beissbarth, Ströbel P, Wittekind C, Hartmann A, Rüschoff J, Papadopoulos T, Rösler E, Ortloff-Kittredge P, Kania U, Schlitt H, Link KH, Bechstein W, Raab HR, Staib L, Germer CT, Liersch T, Sauer R, Rödel C, Ghadimi M, Hohenberger W; German Rectal Cancer Study Group. Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Surgery 2018;53:e181607. *joint first authors (Pubmed-Link).

Klement RJ, Hoerner-Rieber J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble MJ, Eich HC, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl KH, Klass ND, Krempien R, Lohaus E, Petersen C, Schrade E, Wendt TG, Wittig A, Guckenberger M. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiother Oncol 2018;127:246-252 (Pubmed-Link).

Linge A, Schötz U, Löck S, Lohaus F, Neubeck CV, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Lauber K, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Krause M, Belka C, Baumann M; DKTK-ROG. Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiother Oncol 2018;127:27-35 (Pubmed-Link).

Martin D, Balermpas P, Winkelmann R, Rödel F, Rödel C, Fokas E. Anal squamous cell carcinoma – State of the art management and future perspectives. Cancer Treat Rev 2018;65:11-21. (Pubmed-Link).

Martin D, Rödel C, Fokas E. Nivolumab for pretreated metastatic anal cancer : Immune checkpoint blockade is also advised in combination with radiochemotherapy. Strahlenther Onkol. 2018;194:356-57 (Pubmed-Link)

Müller von der Grün J, Bon D, Rödel C, Balermpas P. Patterns of care analysis for head & neck cancer of unknown primary site: a survey inside the German society of radiation oncology (DEGRO) Strahlenther Onkol 2018;94:750-758. (Pubmed-Link).

Müller von der Grün J, Martin D , Stöver T ,Ghanaati S, Rödel C, Balermpas P. Chemoradiotherapy as definitive treatment for elderly patients with head and neck cancer. Biomed Res Int 2018;e3508795 (PubMed-Link).

Moustakis C, Chan MKH, Kim J, Nilsson J, Bergman A, Bichay TJ, Palazon Cano I, Cilla S, Deodato F, Doro R, Dunst J, Eich HT, Fau P, Fong M, Haverkamp U, Heinze S, Hildebrandt G, Imhoff D, de Klerck E, Köhn J, Lambrecht U, Loutfi-Krauss B, Ebrahimi F, Masi L, Mayville AH, Mestrovic A, Milder M, Morganti AG, Rades D, Ramm U, Rödel C, Siebert FA, den Toom W, Wang L, Wurster S, Schweikard A, Soltys SG, Ryu S, Blanck O. Treatment planning for spinal radiosurgery : A competitive multiplatform benchmark challenge. Strahlenther Onkol 2018;194:843-854 (Pubmed-Link).

Murakami N, Ueno T, Yatsuoka W, Okamoto H, Tselis N, Masui K, Yoshida K, Takahashi K, Inaba K, Okuma K, Igaki H, Nakayama Y, Itami J. Dose coverage comparison between "interstitial catheter-only" and "hybrid intracavitary-interstitial brachytherapy" for early stage squamous cell carcinoma of the buccal mucosa. J Contemp Brachytherapy. 2018;10:486-491 (Pubmed-Link).

Niyazi M, Adeberg S, Kaul D, Boulesteix AL, Bougatf N, Fleischmann DF, Grün A, Krämer A, Rödel C, Eckert F, Paulsen F, Kessel KA, Combs SE, Oehlke O, Grosu AL, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J. Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. Radiother Oncol 2018;127:121-127. (Pubmed-Link)

Rödel F, Steinhäuser K, Nina-Naomi Kreis NN, Friemel A, Martin D, Wieland U, Rave-Fränk M, Balermpas P, Fokas E, Louwen F, Claus Rödel C, Yuan J. Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy.  Radiother Oncol 2018;126:214-221 (Pubmed-Link).

Schmidt S, Linge A, Zwanenburg A, Leger S, Lohaus F, Krenn C, Appold S, Gudziol V, Nowak A, von Neubeck C, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch SU, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S. Development and validation of a gene signature for patients with head and neck squamous cell carcinomas treated by postoperative radio(chemo) therapy. Clin Cancer Res 2018;24:1364-1374. (Pubmed-Link)

Sprenger T, Beißbarth T, Sauer R, Tschmelitsch J, Fietkau R, Liersch T, Hohenberger W, Staib L, Gaedcke J, Raab HR, Rödel C, Ghadimi M. Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94. Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94.Br J Surg 2018;105:1510-1518 (Pubmed-Link).

Stangl S, Tontcheva N, Sievert W, Shevtsov M, Niu M, Pigorsch S, Combs S, Haller B, Balermpas P, Rödel F, Rödel C, Fokas E, Krause M, Linge A, Lohhaus F, Baumann M, Tinhofer I, Budach V, Stuschke M, Grosu AL, Abdollahi A, Debus J, Belka C, Lauber K, Mönnich D, Zips D, Multhoff G. Heat shock protein 70 expression and infiltration of CD56+ NK cells as prognostic indicators of survival in patients with squamous cell carcinoma of the head and neck cancer (SCCHN) after adjuvant radiochemotherapy: a multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 2018;142:1911-25. (Pubmed-Link)

Stera S, Balermpas P, Chan MKH, Huttenlocher S, Wurster S, Keller C, Imhoff D, Rades D, Dunst J, Rödel C, Hildebrandt G, Blanck O. Breathing-motion-compensated robotic guided stereotactic body radiation therapy:Patterns of failure analysis. Strahlenther Onkol 2018;194:143-155 (Pubmed-Link).

Strouthos I, Tselis N, Chatzikonstantinou G, Butt S, Baltas D, Bon D, Milickovic N, Zamboglou N. High dose rate brachytherapy as monotherapy for localised prostate cancer. Radiother Oncol 2017; epub ahead of print. (Pubmed-Link)

Strouthos I, Chatzikonstantinou G, Zamboglou N, Milickovic N, Papaioannou S, Bon D, Zamboglou C, Rödel C, Baltas D, Tselis N. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer. Radiother Oncol 2018;126:270-277 (PubMed-Link).

Tselis N, Prott FJ, Ott O, Weiss C, Rödel C. Radiochemotherapy for invasive bladder cancer : An update. Urologe A. 2018;57:679-685 (Pubmed-Link).

Umezawa R, Murakami N, Nakamura S,